A form of lung cancer, which is found in about 10%–15% of Western patients and 40%–50% of Asian patients, is driven by a mutation in the epidermal growth factor receptor (EGFR) gene. Gefitinib is a go-to drug that shuts down this protein's signals. However, over time, cancer cells develop resistance to the drug and keep dividing even while treatment is underway, rendering gefitinib powerless. A recent study published in PLOS One has found a way out of this resistance trap.
❓ Unknown
Deworming Drug Restores Lung Cancer Sensitivity to Targeted Therapy in Mice
2w ago
October 14, 2026
1 min read
📰 Medical Xpress
📋 Key Takeaway
A study published in PLOS One reveals that a common deworming drug can help restore sensitivity to gefitinib in lung cancer cells that have developed resistance. This research is significant as it may lead to improved treatment options for lung cancer patients, including those in Iran, where cancer rates are rising. Understanding advancements in cancer treatment is crucial for healthcare developments in the region.
🔍 Quick Context Guide
💡 Bottom Line:
The study offers hope for enhanced lung cancer treatments, particularly in regions with high incidence rates.
👥 Key Players
Researchers from PLOS One
MENTIONED
Conducted the study
"Their findings could lead to new treatments for lung cancer, which is a growing health issue in Iran."
Patients with lung cancer
MENTIONED
Affected individuals
"They represent a significant portion of the population facing rising cancer rates in Iran."
📰 What Happened
A study found that a common deworming drug can restore sensitivity to gefitinib in lung cancer cells that have become resistant. This discovery may enhance treatment options for lung cancer patients.
- Lung cancer driven by EGFR mutations affects 10%-15% of Western patients and 40%-50% of Asian patients.
- Gefitinib is commonly used but often becomes ineffective due to resistance.
💡 Why It Matters
🇮🇷 For Iran: Improved treatment options could significantly impact the health outcomes for lung cancer patients in Iran.
🌍 Regional: This research could influence cancer treatment protocols across Asia, where lung cancer rates are higher.
🌐 International: Internationally, it highlights the potential for repurposing existing drugs to tackle drug resistance in cancer therapies.
📚 Background
Lung cancer is a leading cause of cancer-related deaths, and drug resistance is a major challenge in effective treatment. Understanding new approaches is crucial for improving patient outcomes.
Cancer treatment advancements
Drug resistance in oncology
📡 Source:
NEUTRAL
📊 Confidence:
70%
PLOS One is a peer-reviewed journal, indicating a level of credibility in the research presented.
🏷️ Entities Mentioned
🌐
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%
📰 Related Coverage
Just now •
Trump: Negotiations with Iran are progressing well but are not trustworthy
7 min ago •
Video/ Ayatollah Akhtari: Some Individuals Stir Up Discord for Personal Reasons
7 min ago •
Fourth Day Program of World Wrestling Championship: One Gold and Three Bronze Chances for Iran
30 min ago •
Bolsonaro Has Fled Brazil with the Help of a Former Mossad Agent
36 min ago •